Centered on the operating holding company Asahi Kasei Corp. and six core operating companies, the Asahi Kasei Group operates in the three business sectors of Material, Homes, and Health Care.
Asahi Kasei Corp. develops fiber products, chemicals, and electronic related materials based on its core technology of chemistry, and globally pursues growth opportunities in the areas where we can leverage our technological advantages. In its holding company function, Asahi Kasei Corp. focuses on strategic planning and analysis, administration of resources, oversight of management execution, and development of new businesses which extend beyond the scope of any single field of business.
- Basic Materials
- Performance Products
- Specialty Solutions
We provide devices and functions that are essential for the manufacturing processes and final products of our customers, through our innovative development, design, and production technology coupled with a robust marketing network. We will continue to build on our established presence to maintain industry leadership in the electronics field.
- Electronic Devices
We are advancing with a high-earnings operational structure and strong brand recognition in the Japanese urban homes market. Our business structure is being transformed to create synergies through further expansion of order-built homes operations, expansion of remodeling, real estate, and financial services, and development of new business.
The focus of our innovation is placed on the development of high-value added products and construction technologies. We provide solution-based products and services to meet increasingly sophisticated customer needs in our four core areas of autoclaved aerated concrete (AAC), foundation systems, insulation materials, and structural components, contributing to enhanced infrastructure in Japan.
- Construction Materials
We are growing as a specialty pharmaceutical firm with a global presence by focusing on the development of new world-class drugs in selected therapeutic fields. In diagnostics, management resources are concentrated on products with strong growth prospects.
Our medical care business contributes to the advancement of medical treatment worldwide via continuous innovation in various fields, including medical device systems that respond to unmet needs (such as chronic and acute renal disease, neurologic diseases and other intractable conditions), filters that improve the quality of blood transfusion products, and products that enable safe and efficient production of biotherapeutics and other medicines at the cutting edge of new drug development.
- Medical Care
A major US manufacturer of critical care devices and systems, ZOLL became a member of the Asahi Kasei Group in April 2012. While sales continue to grow in the U.S. as our principal market, we are building a global presence in the field of acute critical care by expanding our reach throughout Europe and Asia. Through synergy with the other Health Care businesses of Asahi Kasei, we are contributing to the development of this sector as a major pillar of operations.
- Acute Critical Care
A US pharmaceutical company, Veloxis sells an immunosuppressive drug using proprietary drug delivery technology* to help prevent organ rejection after kidney transplants. Veloxis is enhancing licensing activity to obtain new pharmaceuticals as growth drivers to accelerate the Asahi Kasei Group's transformation to a global health care enterprise.
- *Technology to enhance the effects and/or reduce the side effects of drugs by controlling their absorption, distribution, metabolism, and excretion